Rxivist logo

Histone deacetylase inhibitor givinostat attenuates nonalcoholic steatohepatitis and liver fibrosis

By He-ming Huang, Shi-jie Fan, Xiao-ru Zhou, Yan-jun Liu, Xiao Li, Li-ping Liao, Jing Huang, Cui-cui Shi, Liang Yu, Rong Fu, Jian-gao Fan, Yuan-yuan Zhang, Cheng Luo, Guang-ming Li

Posted 11 Jun 2020
bioRxiv DOI: 10.1101/2020.06.09.141655

Non-alcoholic steatohepatitis (NASH) is a common chronic liver disease that causes worldwide morbidity and mortality, yet there is still a lack of pharmacological therapies. Liver inflammation is an important contributor for disease progression from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH). We identified HDAC inhibitor givinostat as a potent inhibitor of macrophages inflammatory activation, and aimed to evaluate the therapeutic potential of givinostat for treatment of NASH. Daily administration of givoinostat (10mg/kg) alleviated inflammation and attenuated hepatic fibrosis in methionine- and choline-deficient diet (MCD)-induced NASH mice. RNA-seq analysis of liver tissues form MCD-fed mice revealed givinostat potently blocked expression of inflammation-related genes and regulated a broad set of lipid metabolism-related genes. In hepatocyte givinostat reduced palmitic acid induced intracellular lipid accumulation. The benefit of givinostat was further confirmed in fructose, palmitate, cholesterol diet (FPC) induced NASH mice. Givinostat attenuated hepatic steatosis, inflammation as well as liver injury in FPC-induced NASH. In conclusion, givinostat appears to be efficacious in reversing diet-induced NASH, and may serve as a therapeutic agent for treatment of human NASH.

Download data

  • Downloaded 106 times
  • Download rankings, all-time:
    • Site-wide: 84,911 out of 92,180
    • In animal behavior and cognition: 1,322 out of 1,436
  • Year to date:
    • Site-wide: 41,774 out of 92,180
  • Since beginning of last month:
    • Site-wide: 13,078 out of 92,180

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide


Sign up for the Rxivist weekly newsletter! (Click here for more details.)